BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

RENATA

All Eps Dividend Board Agm Q1 Q2 Q3

RENATA 28-Oct-2018

(Continuation news of RENATA): The Company has also reported Consolidated EPS of Tk. 44.35, Consolidated NAV per share of Tk. 221.45 and Consolidated NOCFPS of Tk. 38.12 for the year ended on June 30, 2018 as against Tk. 38.24, Tk. 184.82 and Tk. 52.13 respectively for the same period of the previous year. (end)

RENATA 28-Oct-2018

The Board of Directors has recommended 95% cash and 15% stock dividend for the year ended on June 30, 2018. Date of AGM: 15.12.2018, Time: 11:00 AM, Venue: Corporate Headquarters Premises, Plot No. 1, Milk Vita Road, Section-7, Mirpur, Dhaka. Record Date: 15.11.2018. (cont.)

RENATA 17-Oct-2018

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 27, 2018 at 12:00 noon to consider, among others, audited financial statements of the Company for the year ended on June 30, 2018.

RENATA 17-May-2018

Referring to their earlier news disseminated by DSE on 18.01.2018, the Company has further informed that the Board of Directors of the Company has approved to establish a Subsidiary Company in UK fulfilling the regulatory requirement (DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL) to export in the EU countries in the name of Renata (UK) Limited.

RENATA 30-Apr-2018

(Q3 Un-audited): Consolidated EPS was Tk. 11.06 for January-March 2018 as against Tk. 8.87 for January-March 2017; Consolidated EPS was Tk. 31.14 for July 2017-March 2018 as against Tk. 26.26 for July 2016-March 2017. Consolidated NOCFPS was Tk. 26.63 for July 2017-March 2018 as against Tk. 46.79 for July 2016-March 2017. Consolidated NAV per share was Tk. 208.34 as on March 31, 2018 and Tk. 184.82 as on June 30, 2017.

RENATA 23-Apr-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2018 at 12:00 noon to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2018.

RENATA 29-Jan-2018

(Q2 Un-audited): Consolidated EPS was Tk. 9.98 for October-December, 2017 as against Tk. 9.28 for October-December, 2016; Consolidated EPS was Tk. 20.08 for July-December, 2017 as against Tk. 17.39 for July-December, 2016. Consolidated NOCFPS was Tk. 31.18 for July-December, 2017 as against Tk. 34.67 for July-December, 2016. Consolidated NAV per share was Tk. 197.28 as on December 31, 2017 and Tk. 184.82 as on June 30, 2017.

RENATA 22-Jan-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2018 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2017.

RENATA 18-Jan-2018

(Continuation news of RENATA): 3. The Government of Bangladesh has approved the acquisition of two Abbreviated New Drug Applications (ANDAs) by Renata Limited. Accordingly, the Company expects to begin their US business later this year. 4. Two manufacturing sites, viz., Mirpur and the Rajendrapur have been approved by ISO 14001: 2015 (Environmental Management) and BS OHSAS 18001: 2007 (Occupational Health and Safety Management). (end)

RENATA 18-Jan-2018

The Company has informed their following recent developments: 1. Two factories, viz., the Potent Product Facility at Mirpur and the General Facility at Rajendrapur have been approved by the Medicines and Healthcare products Agency (MHRA) of the UK. 2. Renata has received registration for two products in the UK. The sales of Hydrocortisone 10 mg and 20 mg tablets shall begin in February to be followed by Colcichine 500 mg tablets. (cont.)

Previous Next page